Pharmacokinetics and safety of topical fluralaner in koalas <i>(Phascolarctos cinereus</i> <i>)</i>.

ABSTRACT: Sarcoptic mange (etiological agent Sarcoptes scabiei) is among the most important parasitic diseases of some marsupial species and has been an emerging disease of koalas, causing welfare and conservation implications. Fluralaner (Bravecto® MSD Animal Health), an ectoparasiticide of the isoxazoline class, has been demonstrated as a long-lasting and efficacious chemotherapeutic agent against sarcoptic mange in multiple mammal species and may also be beneficial for impacted koalas. Here, we evaluated the pharmacokinetics and clinical safety of fluralaner in koalas. Healthy captive individuals were treated topically with 85 mg/kg fluralaner administered to the interscapular epidermis. Following treatment, fluralaner was detected in plasma using ultra-performance liquid chromatography an

SUBMITTER: Young ET 

PROVIDER: S-EPMC11993836 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature